Skip to content
ClinCalc Pro
Menu
Topical mild steroid + antibacterial + antifungal

Hydrocortisone with chlorhexidine and nystatin

Brand names: Nystaform-HC

Used in: Anaphylaxis & Allergy

This combination preparation pairs the mild corticosteroid hydrocortisone with the antiseptic chlorhexidine and the antifungal nystatin, used for inflammatory skin conditions complicated by candidal and bacterial infection, such as intertrigo and napkin dermatitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Hydrocortisone reduces local inflammation via glucocorticoid receptors, chlorhexidine disrupts bacterial cell membranes, and nystatin binds ergosterol to create membrane pores that kill Candida.

Prescribing in practice

  • Reserve the steroid-containing combination for inflamed skin with confirmed or strongly suspected candidal and bacterial involvement, and use short term to avoid steroid-related skin atrophy in flexures and the nappy area.
  • Nystatin treats Candida but is inactive against dermatophytes, so confirm the infecting organism.
  • Avoid on broken skin where chlorhexidine absorption or irritation may be increased.

Monitoring

Review the treated area for resolution of both inflammation and infection and step down the steroid once settled.

Counselling the patient

  • Apply thinly to the affected folds and keep the area clean and dry.
  • Use only for the short period advised, not as a long-term cream.
  • Return if the rash spreads or does not improve.

Evidence & guidelines

Combined topical steroid-antimicrobial products are reserved for inflammatory dermatoses with secondary infection, consistent with standard prescribing references.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.